Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.

Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.

The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.

There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.

The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.

This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.

Share:
More In Business
Stretching Your Dollar: What to Know About Changes to FAFSA
Applying for financial aid for college is a long process but there's a new streamlined application for federal student aid. Mark Kantrowitz, student loan expert, joined Cheddar News to explain the FAFSA form and what kind of changes are expected.
Stretching Your Dollar: Caring for Your Pets This Holiday Season
With all of the stress surrounding the holiday season with gift-buying and planning family gatherings, it could be a chaotic time for all members of your family, including pets. Cesar Milan and Michael Ehrman, co-founders of Halo Collar, joined Cheddar News to provide tips on how to keep your pets stress-free for the upcoming holiday season.
Load More